As antimicrobial resistance accelerates, when every hour can matter, faster diagnostics can help clinicians get patients on the right antibiotics sooner

随着抗菌药物耐药性加速蔓延，在分秒必争的情况下，更快的诊断手段有助于临床医生让患者尽早接受合适的抗生素治疗

Vivid Dx's direct-from-blood platform uses light and AI to identify dangerous pathogens, aiming to move infectious disease care from broad-spectrum empiric therapy to targeted treatment

Vivid Dx 的直血检测平台利用光学技术和人工智能识别危险病原体，旨在将感染性疾病诊疗从广谱经验性治疗转向靶向治疗。

Keith O'Neill appointed as CEO to lead Vivid Dx through clinical validation and toward commercialization, drawing on 25 years of international experience advancing healthcare innovation

基思·奥尼尔被任命为首席执行官，将凭借其在推动医疗创新方面积累的25年国际经验，带领Vivid Dx完成临床验证并推进商业化进程。

OXFORD, England

牛津，英格兰

,

，

July 28, 2026

2026年7月28日

/PRNewswire/ --

/美通社/ --

Vivid Dx

生动诊断

, a precision diagnostics company transforming pathogen detection and antimicrobial resistance (AMR) testing, today announced $15 million in seed financing co-led by Oxford Science Enterprises and Cedars-Sinai Intellectual Property Co., with participation from Jameel Investment Management Company and additional strategic investors.

一家致力于变革病原体检测和抗菌药物耐药性（AMR）测试的精准诊断公司，今日宣布完成1500万美元的种子轮融资。该轮融资由牛津科学企业（Oxford Science Enterprises）和塞达斯-西奈知识产权公司（Cedars-Sinai Intellectual Property Co.）联合领投，贾米尔投资管理公司（Jameel Investment Management Company）及其他战略投资者参与投资。

The company also announced the appointment of scientist and diagnostics executive Keith O'Neill as chief executive officer to lead its next phase of clinical and commercial development..

该公司还宣布任命科学家兼诊断业务高管基思·奥尼尔（Keith O'Neill）为首席执行官，以领导其下一阶段的临床和商业化发展。

When a patient may have sepsis, every hour matters. Hospitals often have to wait days to learn which pathogen is causing the infection and which antibiotics are most likely to work. During that window, clinicians are forced to treat without complete information, often relying on broad-spectrum antibiotics that may not work against drug-resistant infections.

当患者可能患有脓毒症时，每一小时都至关重要。医院往往需要等待数天才能确定是哪种病原体导致了感染，以及哪种抗生素最有可能有效。在此期间，临床医生不得不在信息不全的情况下进行治疗，常常依赖广谱抗生素，而这些药物可能对耐药性感染无效。

This delay is a major public health issue: researchers estimate antimicrobial resistance (AMR) could contribute to .

这一延误是一个重大的公共卫生问题：研究人员估计，抗菌药物耐药性（AMR）可能导致。

39 million deaths globally between 2025 and 2050

2025年至2050年间全球3900万人死亡

. As hospitals face

随着医院面临

tighter antibiotic stewardship requirements

更严格的抗生素管理要求

and growing pressure to protect

以及日益增长的保护压力

last-line therapies

末线疗法

, faster diagnostics are becoming essential to giving patients the right treatment sooner while helping slow the spread of resistance.

更快的诊断对于让患者尽早获得正确治疗，同时帮助减缓耐药性的传播，正变得至关重要。

Rapid infectious disease diagnostics have long faced a difficult challenge: hospitals need faster answers, but those answers also need to be accurate, broad enough to guide treatment, and practical for clinical workflows. Vivid Dx is addressing that challenge by applying AI/ML and advanced sample preparation to .

快速传染病诊断长期以来面临着一个严峻的挑战：医院需要更快的检测结果，但这些结果还必须准确、足够全面以指导治疗，并符合临床工作流程的实际需求。Vivid Dx 正通过应用人工智能/机器学习以及先进的样本制备技术来应对这一挑战。

Raman spectroscopy

拉曼光谱

, a validated technology with the capability to read biochemical signatures from individual pathogen cells. By combining direct-from-blood pathogen isolation, proprietary Raman spectral databases, and AI-powered signal interpretation, Vivid Dx's platform is designed to identify pathogens and support phenotypic antimicrobial susceptibility testing (AST) directly from blood, with the goal of reducing testing timelines from days to hours..

，这是一项经过验证的技术，能够从单个病原体细胞中读取生化特征。通过结合直接从血液中分离病原体、专有的拉曼光谱数据库以及人工智能驱动的信号解读，Vivid Dx的平台旨在直接从血液中识别病原体并支持表型抗菌药物敏感性试验（AST），从而将检测时间从数天缩短至数小时。

For hospitals, those earlier insights could help clinicians move from broad-spectrum empiric therapy to targeted treatment sooner, potentially reducing ICU stays, lowering treatment costs, and improving patient outcomes. Faster, more precise treatment decisions could also reduce unnecessary antibiotic exposure, an important factor in slowing the evolution of AMR..

对医院而言，这些早期的洞察可以帮助临床医生更快地从广谱经验性治疗转向针对性治疗，从而可能缩短重症监护室（ICU）住院时间、降低治疗成本并改善患者预后。更快、更精准的治疗决策还可以减少不必要的抗生素暴露，这是延缓抗微生物药物耐药性（AMR）演化的一个重要因素。

'For decades, clinicians treating serious infections have had to wait too long for the information needed to guide antibiotic treatment. The biggest delay in today's workflow happens before many diagnostic systems can even begin: clinicians are waiting for culture,' said Keith O'Neill, incoming chief executive officer of Vivid Dx.

“数十年来，临床医生在治疗严重感染时，不得不等待过长时间才能获得指导抗生素治疗所需的信息。当前工作流程中最大的延误发生在许多诊断系统甚至尚未启动之前：临床医生正在等待培养结果。”Vivid Dx 即将上任的首席执行官基思·奥尼尔表示。

'Our goal is to move those answers closer to the moment a blood sample is taken. The company has built strong technical foundations, and my focus will be advancing that work through clinical validation and toward a platform that clinicians can adopt routinely to inform patient care decisions.'.

“我们的目标是将这些答案的获取时间提前至采集血液样本的时刻。该公司已奠定坚实的技术基础，而我的工作重点将是推进这项工作的临床验证，并打造一个可供临床医生常规采用的平台，从而为患者护理决策提供依据。”

O'Neill's appointment brings Vivid Dx experience spanning scientific research, diagnostics development, global healthcare innovation, and company building. He worked at MIT on the Human Genome Project, built a multi-institution point-of-care diagnostics program, supported early-stage life sciences companies through Enterprise Ireland, and built global innovation alliances at Abbott.

奥尼尔的任命为Vivid Dx带来了涵盖科学研究、诊断产品开发、全球医疗创新以及企业建设的丰富经验。他曾在麻省理工学院参与人类基因组计划，构建了一个多机构的即时诊断项目，通过爱尔兰企业局支持早期生命科学公司，并在雅培公司建立了全球创新联盟。

Most recently, he served as CEO of Novus Diagnostics, where he advanced the development of a rapid point-of-care test for bloodstream infections..

最近，他担任Novus Diagnostics的首席执行官，推动了用于血流感染的快速即时检测技术的发展。

Vivid Dx is now preparing to test its platform with patient-derived clinical samples, a key step toward showing that the technology can perform in the kinds of complex cases hospitals see every day. To date, the company has achieved proof-of-concept across core platform components, including direct-from-blood pathogen isolation, high-purity bacterial recovery, AI-powered Raman signal enhancement, and development of a proprietary spectral database containing thousands of clinical isolates.

Vivid Dx 目前正筹备利用患者来源的临床样本对其平台进行测试，这是证明该技术能够在医院日常面临的复杂病例中有效运作的关键一步。迄今为止，该公司已在核心平台组件上实现了概念验证，包括直接从血液中分离病原体、高纯度细菌回收、人工智能驱动的拉曼信号增强，以及开发包含数千种临床分离株的专有光谱数据库。

In preclinical testing, the platform demonstrated approximately 99% pathogen identification accuracy, and roughly 92% concordance for phenotypic AST testing compared with gold-standard methods..

在临床前测试中，该平台展现出约99%的病原体识别准确率，并且与金标准方法相比，其表型药敏试验（AST）结果的一致性约为92%。

'Vivid Dx has built strong technical proof across the core platform and is now advancing toward clinical validation,' said Tony Besse, Principal, Health Tech at Oxford Science Enterprises. 'The need for faster infectious disease testing is urgent, but speed alone is not enough—hospitals need results they can trust and integrate into care pathways.

牛津科学企业公司（Oxford Science Enterprises）健康技术主管托尼·贝塞表示：“Vivid Dx 已在核心平台上建立了坚实的技术验证，目前正朝着临床验证阶段迈进。对更快进行传染病检测的需求十分迫切，但仅有速度是不够的——医院需要的是值得信赖并能整合到诊疗路径中的检测结果。”

We look forward to supporting Vivid Dx as it takes the next step from technical proof toward the evidence needed for adoption at scale.'.

我们期待支持 Vivid Dx 迈出从技术验证到大规模应用所需证据的关键一步。

'Over the next decade, it's crucial that physicians globally adopt technologies that can help identify pathogens and guide therapy decisions faster and more precisely for drug-resistant infections,' said Nirdesh Gupta, Managing Director, Cedars-Sinai Technology Ventures at Cedars-Sinai. 'We see significant potential in Vivid Dx's approach combining blood-based testing and AI-driven analysis, and look forward to seeing the platform progress through clinical validation as it works to support faster, more informed infectious disease treatment decisions.'.

“在未来十年，全球医生采用能够帮助更快、更精准地识别病原体并指导耐药感染治疗决策的技术至关重要。”西奈山医疗中心（Cedars-Sinai）旗下西奈山科技创投（Cedars-Sinai Technology Ventures）的总经理Nirdesh Gupta表示。“我们看到Vivid Dx将血液检测与人工智能驱动分析相结合的方法具有巨大潜力，并期待该平台在推进临床验证的过程中取得进展，从而支持更快、更具依据的传染病治疗决策。”

About Vivid Dx

关于 Vivid Dx

Vivid Dx is a precision diagnostics company developing rapid infectious disease testing to help hospitals identify dangerous pathogens and guide faster antibiotic decisions. The company has developed a direct-from-blood platform designed to use Raman spectroscopy and AI to detect infections and support phenotypic antimicrobial susceptibility testing, with the goal of reducing diagnostic timelines from days to hours.

Vivid Dx 是一家精准诊断公司，致力于开发快速传染病检测技术，以帮助医院识别危险病原体并加速抗生素决策。该公司开发了一个直接基于血液的检测平台，旨在利用拉曼光谱和人工智能技术检测感染并支持表型抗菌药物敏感性测试，目标是将诊断时间从数天缩短至数小时。

Vivid Dx's work is focused on improving treatment decisions for life-threatening infections such as sepsis while helping address the growing threat of antimicrobial resistance. Vivid Dx is backed by Oxford Science Enterprises, Cedars-Sinai, Jameel Investment Management Company, and additional strategic investors.

Vivid Dx 的工作重点在于改善脓毒症等危及生命的感染的治疗决策，同时帮助应对日益严峻的抗菌药物耐药性威胁。Vivid Dx 获得了牛津科学企业（Oxford Science Enterprises）、西达赛奈医疗中心（Cedars-Sinai）、贾米尔投资管理公司（Jameel Investment Management Company）以及其他战略投资者的支持。

Learn more at .

了解更多，请访问。

vivid-dx.com

vivid-dx.com

.

。

Media contact:

媒体联系人：

[email protected]

[email protected]

SOURCE Vivid Dx

来源：Vivid Dx

21

二十一

%

百分比

more press release views with

更多新闻稿浏览量，通过

Request a Demo

申请演示